See more : Euromax Resources Ltd. (EOX.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Pasithea Therapeutics Corp. (KTTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pasithea Therapeutics Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Maruichi Steel Tube Ltd. (5463.T) Income Statement Analysis – Financial Results
- Moorim Paper Co., Ltd. (009200.KS) Income Statement Analysis – Financial Results
- Direct Line Insurance Group plc (DIISY) Income Statement Analysis – Financial Results
- Cameco Corporation (CCJ) Income Statement Analysis – Financial Results
- FOLLI FOLLIE Commercial Manufacturing And Technical Société Anonyme (FLLIY) Income Statement Analysis – Financial Results
Pasithea Therapeutics Corp. (KTTA)
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 486.56K | 15.06K | 0.00 |
| Cost of Revenue | 648.45K | 113.20K | 17.28K | 0.00 |
| Gross Profit | -648.45K | 373.36K | -2.21K | 0.00 |
| Gross Profit Ratio | 0.00% | 76.74% | -14.69% | 0.00% |
| Research & Development | 8.10M | 2.67M | 0.00 | 0.00 |
| General & Administrative | 7.88B | 9.92M | 0.00 | 0.00 |
| Selling & Marketing | -7.87B | 2.60M | 0.00 | 0.00 |
| SG&A | 7.88M | 12.52M | 4.51M | 40.98K |
| Other Expenses | 0.00 | 44.72K | 0.00 | 0.00 |
| Operating Expenses | 15.98M | 15.19M | 4.51M | 40.98K |
| Cost & Expenses | 15.98M | 15.30M | 4.52M | 40.98K |
| Interest Income | 0.00 | 102.00 | 508.00 | 0.00 |
| Interest Expense | 0.00 | 102.00 | 508.00 | 0.00 |
| Depreciation & Amortization | 648.45K | 5.09K | 1.38K | 61.48K |
| EBITDA | -15.33M | -12.58M | -4.51M | 0.00 |
| EBITDA Ratio | 0.00% | -3,029.28% | -29,916.57% | 0.00% |
| Operating Income | -15.98M | -14.82M | -4.51M | -40.98K |
| Operating Income Ratio | 0.00% | -3,045.12% | -29,925.73% | 0.00% |
| Total Other Income/Expenses | 471.61K | 861.09K | 2.33M | -4.00 |
| Income Before Tax | -15.51M | -13.94M | -2.17M | -40.98K |
| Income Before Tax Ratio | 0.00% | -2,864.29% | -14,430.49% | 0.00% |
| Income Tax Expense | 0.00 | -879.97K | 508.00 | -61.48K |
| Net Income | -15.96M | -13.06M | -2.17M | -40.98K |
| Net Income Ratio | 0.00% | -2,683.43% | -14,433.87% | 0.00% |
| EPS | -12.65 | -10.34 | -1.89 | -0.06 |
| EPS Diluted | -13.01 | -10.34 | -1.89 | -0.06 |
| Weighted Avg Shares Out | 1.26M | 1.26M | 1.15M | 688.92K |
| Weighted Avg Shares Out (Dil) | 1.23M | 1.26M | 1.15M | 688.92K |
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
-- SRC recommended that the trial escalate to the next dose level of 15mg capsule -- -- No dose-limiting toxicities (DLTs) observed to date -- -- No rash observed to date -- MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Pasithea...
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today...
Why Is Pasithea Therapeutics Stock Surging On Thursday?
On Thursday, Pasithea Therapeutics Corp. KTTA announced safety, tolerability, pharmacokinetic (PK), and preliminary efficacy data from the first 2 cohorts of patients (n=6) in its Phase 1 trial of PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a...
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
-- Single patient in 2mg cohort with stage 3 colon cancer who received 4 prior lines of therapy achieves prolonged stable disease and remains on drug into 6th dosing cycle -- -- No treatment-related adverse events (TRAEs) or dose-limiting toxicities...
Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
Pasithea completes chronic toxicity studies for PAS-004, showing safety and potential for long-term use in NF1 and cancer treatment; Phase 1 trial ongoing
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
Pasithea Tx appoints Dr. Rebecca Brown, an expert in Neurofibromatosis and Director at Mount Sinai, to its Scientific Advisory Board to aid in PAS-004.
Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”) a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1)...
Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
Pasithea to present preclinical data at ASCO 2024 showing PAS-004 superior inhibition of NRAS cancer cells and xenograft tumors compared to current MEKi's
Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 (NF1)...
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.
Source: https://incomestatements.info
Category: Stock Reports